Evonik reported higher earnings for the first quarter of 2025, citing volume gains, improved pricing in animal nutrition, and continued cost discipline. Adjusted EBITDA increased 7 percent year over year to €560 million, and free cash flow rose 53 percent to €195 million. Revenue remained stable at €3.78 billion.

“We had a good start to the year,” said Chief Executive Officer Christian Kullmann. “However, the combination of a looming global trade war and armed conflicts makes planning for the future more uncertain than ever.”

Evonik confirmed its 2025 earnings outlook of €2.0 billion to €2.3 billion in adjusted EBITDA. Net income rose to €233 million from €156 million in the prior-year quarter. The adjusted EBITDA margin increased to 14.8 percent.

The company reported strong performance in its Nutrition & Care division, where sales rose 12 percent to €1,007 million, and adjusted EBITDA increased 35 percent to €197 million. The Specialty Additives division saw a 1 percent increase in both sales and EBITDA, supported by higher demand from the coatings and crosslinkers markets. Smart Materials remained stable in sales but reported a 7 percent decline in EBITDA due to the absence of licensing income.

Evonik cited internal efficiency efforts and restructuring—including the elimination of division-level management and a leaner corporate structure—as key to maintaining its strategic direction.

Learn more details here.